Webinar

Design It. Degrade It. Prove It.
An Integrated Chemistry and Biology Platform for PROTAC and Molecular Glue Discovery.
Tuesday, 1 December 2026
16:00 CET / 10:00 AM EST / 7:00 AM PST
About the webinar
Targeted protein degradation (TPD) is transforming drug discovery by enabling the selective elimination of disease-driving proteins, including targets long considered beyond the reach of conventional therapeutics.
Yet the successful discovery of degraders requires far more than innovative chemistry. It depends on the seamless integration of molecular design, biological validation, and translational profiling strategies.
In this webinar, Symeres and Axxam will present their integrated degrader discovery platform, bringing together expertise in medicinal chemistry, assay development, high-throughput screening, and ADME-PK characterization to accelerate the identification and optimization of PROTACs and molecular glues.
Through case studies and practical examples, we will discuss how efficient design-make-test-analyse (DMTA) cycles, rational linker optimization, advanced screening technologies, and orthogonal validation assays can help overcome common challenges in degrader programs. We will also highlight how early profiling, developability assessments and formulation expertise support the progression of promising compounds from hit identification to proof-of-concept studies
What you will learn
- How integrated chemistry and biology workflows accelerate the discovery and optimization of PROTACs and molecular glues.
- How advanced screening platforms and orthogonal assays enable robust identification and validation of degrader candidates.
- How iterative optimization, ADME-PK profiling, and formulation strategies help translate promising degraders into viable preclinical candidates.
Keywords
Targeted Protein Degradation, PROTAC, Molecular Glues, Degrader Discovery, Degrader Solutions, Degrader Optimization, E3 Ligases, Linker Optimization, Ternary Complex Formation, Degradation Assays, Linker Chemistry, Degrader Support, Degrader CRO
Meet the speakers
Rutger Folmer – Director of Chemistry, Symeres
Valeria Wanke – Team Leader, Biochemistry, Axxam

Rutger Folmer obtained his PhD in biophysical chemistry, studying DNA-binding proteins using NMR. After a brief period working in bioinformatics at Unilever, he spent 20 years with AstraZeneca in Gothenburg, managing various constellations of structural biology groups, with focus on biophysical techniques and fragment-based lead generation.
In 2017, Rutger joined Mercachem, now Symeres, where he is Director of Chemistry. He has extensive experience in medicinal chemistry, having led medicinal chemistry teams and contributed to numerous drug discovery programs. He is closely involved in the development of Symeres’ targeted protein degradation toolbox

Valeria Wanke PhD, is Team Leader of the Biochemistry Team within the Assay Development Group at Axxam. She holds a PhD in Biotechnology and has over 25 years of experience in biotechnology and drug discovery. Her expertise spans the strategic design and development of biochemical assays for high-throughput screening (HTS) across a broad range of therapeutically relevant targets, including enzymes, protein complexes, and protein–protein and protein–nucleic acid interactions. She also has extensive experience in recombinant protein production and characterisation, scientific team leadership, research project management, and international collaborations
